Celltrion teams up with another Korean biopharma in antibody discovery deal
2023-03-14
上市批准临床2期免疫疗法
Two Korean companies have signed a joint R&D discovery agreement, with the potential to earn in the nine-figures.
Clinical-stage biopharma Genuv has partnered up with Celltrion to discover antibodies using the former’s Shine Mouse platform, which they hope could potentially open up more R&D projects together in the future. There’s no upfront cash, but Genuv will receive milestone payments of up to $25 million if Celltrion decides to option a program into the clinic, and up to $680 million in milestones per program if its sales surpass $7.5 billion.
Genuv, which is focused on oncology and neurodegenerative diseases, already has several antibodies in its pipeline: GNUV205, a tumor-specific IL-2-based immunocytokine anticancer drug and another anti-PD-1 drug candidate GNUV201.
According to Genuv, the company’s platform “generates antibodies with greater diversity compared to those developed with conventional mice.” The company is also nearing the completion of a second platform, called NuvoFc, for bi- and multi-specifics. NuvoFc skips the mice and directly discovers human antibodies.
“We are excited to embark on our mouse platform business with Celltrion as our first partner,” Sungho Han, Genuv founder and CEO, said in a statement. “We believe Celltrion’s in-depth knowledge and experiences in antibody development and production and Genuv’s expertise in novel antibody discovery with our SHINE MOUSETM platform could generate great synergies in providing innovative antibody therapeutics.”
Genuv lists
seven total candidates
in its pipeline, including SNR1611, a MEK1/2 inhibitor in Phase II trials for ALS and in the IND-enabling phase for Alzheimer’s.
Celltrion has been on the expansion path over the last several years, with an investment of
$453 million
in 2020 into building a new research center and manufacturing facility in its home city of Incheon, Korea. In 2019, the company blueprinted a
$514 million
biologics plant in China.
In 2020
, honorary chairman Jung Jin Seo laid out his vision for the company over the next decade with a goal of launching one biosimilar product every year, reaching a total number of 18 products by 2030. It appears to be on its way to Seo’s goal with seven biosimilars described on its website so far.
In September of last year, regulators approved Celltrion’s biosimilar Vegzelma in six cancer types, the company’s third cancer biosimilar approved in the US.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。